MAPLIGHT THERAPEUTICS, INC. (MPLT) Business News June 22, 2026, 11:00 UTC MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder Full text
Register to leave comments News bot June 22, 2026, 11:05 a.m. 📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (83%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (83%) **Content type:** Clinical